Drug name: ATRA + AZ628

Related CSCTT Targets

SOX2 [ref.1]P48431

Tretinoin, ATRA, All Trans Retinoic Acid

Cas.no PubChem ID
302-79-4 444795
Known Target
Retinoic acid receptor RXR-betaP28702
Retinoic acid receptor RXR-gammaP48443
Retinoic acid receptor gammaP13631
Retinal dehydrogenase 1P00352
Retinoic acid-induced protein 3Q8NFJ5
Nuclear receptor subfamily 0 group B member 1P51843
Retinal dehydrogenase 2O94788
Retinoic acid receptor responder protein 1P49788
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). Retinoids such as tretinoin are important regulators of cell reproduction, proliferation, and differentiation and are used to treat acne and photodamaged skin and to manage keratinization disorders such as ichthyosis and keratosis follicularis. Tretinoin also represents the class of anticancer drugs called differentiating agents and is used in the treatment of acute promyelocytic leukemia (APL).


Cas.no PubChem ID
878739-06-1 11676786
Known Target
Serine/threonine-protein kinase B-rafP15056
RAF proto-oncogene serine/threonine-protein kinaseP04049
Vascular endothelial growth factor receptor 2P35968
AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc.


  • [1] Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. Bhat-Nakshatri, P., et al. (2013).Sci Rep.3:2530.
    23982413. [ 23982413 ]

Back to top